Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics (APGE)
NASDAQ:APGE
APGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.10 - $63.50
Previous CloseN/A
Volume109.80K
Average Volume (3M)749.48K
Market Cap
$2.22B
Enterprise Value$2.82B
Total Cash (Recent Filing)$151.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 19, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding46,016,540
10 Day Avg. Volume700,420
30 Day Avg. Volume749,483
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.02
Forecast
1Y Price Target
$94.43Price Target Upside165.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Apogee Therapeutics News
PremiumCompany Announcements
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress
PremiumCompany Announcements
Apogee Therapeutics Reports Positive Phase 1 Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsApogee once again exceeded expectations with the impressive Phase I APG990 data.
Management PerformanceThis management team has done nothing but exceed expectations and execute on all fronts, potentially enabling Apogee to become a generational biotech and generate tens of billions of dollars of value.
Market PotentialAPG777 monotherapy has the potential to reach $10B+ of peak sales alone.
Bears Say
Financial PerformanceAPGE reported a wider net loss in FY2024 ($182.1M vs $84.0M in FY2023) due to increased R&D investment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $29.10 and its highest was $63.50 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $2.22B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 46 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Mar 03, 2025. The company reported -$1.18 earnings per share for the quarter, beating the consensus estimate of -$1.189 by $0.009.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.24.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 46,016,540 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.18 in its last earnings report, beating expectations of -$1.189. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
---
Apogee Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.43 (165.18% Upside)
$94.43 (165.18% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $990.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.25%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
87.83%
Trailing 12-Months
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$94.43
▲(165.18% Upside)
Technical Analysis
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+23.80%
reiterated a buy rating last month
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +23.80% per trade.
---